Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GenBioPro Suit Against FDA May Preserve Generic Mifepristone Approval

Generic Sales To Be Banned On 21 April Without Supreme Court Intervention

Executive Summary

GenBioPro has filed a lawsuit against the FDA to try and preserve the approval of its generic mifepristone product, should the Supreme Court allow an order from a Texas judge to overrule the Food and Drug Administration’s approval of the drug.

You may also be interested in...

GenBioPro Sues FDA To Keep Generic Mifepristone Available; Supreme Court Delays Its Decision

GenBioPro asks Maryland district court to prevent FDA from taking enforcement actions against it if Supreme Court allows stay of approval of mifepristone. Justice Samuel Alito extends deadline to respond until midnight Friday.

FDA's Woodcock To Supreme Court: Mifepristone Ruling Will Create 'Significant Chaos’

Supreme Court stays Texas district court’s order until 19 April. FDA’s deputy principal commissioner says if it goes into effect, sponsors will have to submit additional applications, prescribers may need to be recertified, and FDA will have to reinstate higher dosing regimen.

Fifth Circuit Mifepristone Ruling May Temporarily Halt Pharmacy Dispensing, Generic Approval

Appeals court reverses district court’s stay of FDA’s approval of the medication abortion pill but pauses all agency actions taken since 2016, including changes to REMS and approval of GenBioPro’s generic mifepristone. DOJ and Danco are appealing to the Supreme Court on Friday.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts